| Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle |
13 |
| Robotic surgery in urology: facts and reality. What are the real advantages of robotic approaches for prostate cancer patients? |
11 |
| Prostate cancer immunotherapy: where are we and where are we going? |
11 |
| Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition |
10 |
| Tissue engineering approaches for treating pelvic organ prolapse using a novel source of stem/stromal cells and new materials |
10 |
| Computer-assisted surgery: virtual- and augmented-reality displays for navigation during urological interventions |
9 |
| Relationship of surgeon/hospital volume with outcomes in uro-oncology surgery |
9 |
| Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing |
8 |
| Nutrition, physical activity, and lifestyle factors in prostate cancer prevention |
8 |
| Urinary biomarkers in bladder cancer: where do we stand? |
7 |
| Engaging telehealth to drive value-based urology |
6 |
| Lynch syndrome and urologic malignancies: a contemporary review |
6 |
| Prostate-specific membrane antigen theranostics: therapy with lutetium-177 |
6 |
| Prostate cancer multifocality, the index lesion, and the microenvironment |
6 |
| What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence |
6 |
| New concepts in regenerative medicine approaches to the treatment of female stress urinary incontinence |
6 |
| Comprehensive training in robotic surgery |
6 |
| Optimizing prostate biopsy techniques |
6 |
| Penile cancer epidemiology and risk factors: a contemporary review |
5 |
| Organ-sparing surgical and nonsurgical modalities in primary penile cancer treatment |
5 |
| Prehabilitation for major abdominal urologic oncology surgery |
5 |
| Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies |
5 |
| The interaction of gender and smoking on bladder cancer risks |
5 |
| Immunotherapy for kidney cancer: status quo and the future |
5 |
| Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection |
5 |
| Update on epidemiologic considerations and treatment trends in testicular cancer |
4 |
| Pediatric calculi: cause, prevention and medical management |
4 |
| Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases |
4 |
| Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature |
4 |
| Prostatic artery embolization for benign prostatic hyperplasia: a review |
4 |
| Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer |
4 |
| Current treatment of pediatric bladder and prostate rhabdomyosarcoma (bladder preserving vs. radical cystectomy) |
4 |
| Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors |
4 |
| What is new in robot-assisted radical prostatectomy: a narrative review |
4 |
| Nomograms in urologic oncology, advantages and disadvantages |
4 |
| Modern imaging techniques in urinary stone disease |
4 |
| Ho:YaG laser lithotripsy: recent innovations |
4 |
| Residual stone fragments: clinical implications and technological innovations |
4 |
| Is cytoreductive nephrectomy relevant in the immunotherapy era? |
3 |
| Perioperative antibiotic prophylaxis for stone therapy |
3 |
| Dusting, fragmenting, popcorning or dustmenting? |
3 |
| Tract sizes in percutaneous nephrolithotomy: does miniaturization improve outcome? |
3 |
| The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer |
3 |
| The challenge of stress incontinence and pelvic organ prolapse: revisiting biologic mesh materials |
3 |
| Prevention of bladder cancer incidence and recurrence: tobacco use |
3 |
| The genomics of renal cell carcinoma and its role in renal mass biopsy |
3 |
| Focal therapy of prostate cancer |
3 |
| Focal therapy for prostate cancer: concepts and future directions |
3 |
| Contemporary techniques and outcomes of robotic cystectomy and intracorporeal urinary diversions |
3 |
| Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology |
3 |
